Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22193171 | 0.63 | ALDH1A1 (0.57) | TYMSXDH | |
| SCHEMBL65614 | 0.61 | GDA (0.40) | TYMSXDH | |
| SCHEMBL11683430 | 0.61 | ALDH1A1 (0.42) | TYMSXDH | |
| SCHEMBL9382400 | 0.58 | KMT2A (0.45) | — | |
| SCHEMBL8128626 | 0.57 | ALDH1A1 (0.46) | TYMSXDH | |
| SCHEMBL8138380 | 0.57 | GAA (0.69) | XDH | |
| SCHEMBL19957234 | 0.57 | XDH (0.42) | TYMSXDH | |
| SCHEMBL546663 | 0.56 | TYMS (0.40) | TYMSXDH | |
| SCHEMBL28969 | 0.56 | PDPK1 (0.41) | TYMSXDH | |
| SCHEMBL11567738 | 0.56 | FGFR1 (0.38) | TYMSXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161209-A1 | Compositions inducing cleavage of RNA motifs | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | claimed |
| JP-2002510207-A | — | — | 2002-04-02 | — | — | JP | claimed |
| US-6300483-B1 | FORM, IN COMBINATION WITH AN RNA SUBSTRATE, A STRUCTURE RESEMBLING A HAMMERHEAD STRUCTURE; ANTISENSE THERAPY | RIBOZYME PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | claimed |
| EP-1019497-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1998058057-A9 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LAB INC (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998058057-A1 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LABORATORIES, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1998058058-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| US-20020161209-A1 | Compositions inducing cleavage of RNA motifs | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6441158-B1 | OLIGOPEPTIDE | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6300483-B1 | FORM, IN COMBINATION WITH AN RNA SUBSTRATE, A STRUCTURE RESEMBLING A HAMMERHEAD STRUCTURE; ANTISENSE THERAPY | RIBOZYME PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-1019497-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999033971-A1 | OLIGOMERS THAT BIND TO KU PROTEIN | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998058057-A9 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LAB INC (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998058057-A1 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LABORATORIES, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998058058-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161209-A1 | Compositions inducing cleavage of RNA motifs | NSUN2, NSUN3, RNGTT | TYMS 567/4885XDH 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.